Fragile X Syndrome
A condition characterized genotypically by mutation of the distal end of the long arm of the X chromosome (at gene loci FRAXA or FRAXE) and phenotypically by cognitive impairment, hyperactivity, SEIZURES, language delay, and enlargement of the ears, head, and testes. INTELLECTUAL DISABILITY occurs in nearly all males and roughly 50% of females with the full mutation of FRAXA. (From Menkes, Textbook of Child Neurology, 5th ed, p226)
Drugs by status
Phase 4 trials (6)
Phase 3 trials (7)
Phase 2 trials (20)
Phase 1 trials (8)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (7)
Organization Involved with Phase 2 Indications (41)
- Roche
- Alcobra Ltd.
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Marinus Pharmaceuticals
- Neuren Pharmaceuticals Limited
- Neuropharm
- Ovid Therapeutics Inc.
- RespireRx
- Tetra Discovery Partners
- FRAXA Research Foundation
- National Institutes of Health (NIH)
- National Institute of Mental Health (NIMH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- United States Army
- University of Pennsylvania
- Baylor University
- Harvard University
- Emory University
- Geisinger Clinic
- University of Washington
- Stanford University
- University of Michigan
- University of Nebraska
- University of Alberta
- University of California, Los Angeles
- Vanderbilt University
- The Mediterranean Institute for the Advance of Biotechnology and Health Research
- Icahn School of Medicine at Mount Sinai
- Greenwood Genetic Center
- Red Oak Psychiatry
- +11 more
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (6)